CAMBRIDGE, MA – October 30, 2025 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company, today announces the addition of three distinguished leaders in the field of inflammation and immunology to its Scientific Advisory Board (SAB): Peter Taylor, PhD, Marco Londei, MD, and Deepak Rao, MD, PhD. The new members join an esteemed group of advisors to provide strategic insight and guidance for the progression of HiFiBiO’s I&I pipeline, including HFB302401, a potential best-in-class KLRG1 biparatopic depletor currently in preclinical development.
“We are honored to welcome such a renowned group of experts to HiFiBiO’s Scientific Advisory Board,” said Francisco Adrián, Chief Scientific Officer of HiFiBiO Therapeutics. “The addition of their unique expertise and insights across the I&I field strengthens our ability to advance transformative immunotherapies for patients in need.”
Alongside these new appointments, Aurélien Marabelle, MD, PhD, Giovanni Abbadessa, MD, PhD, and Wendye Robbins, MD, have transitioned off the SAB. We extend our sincere gratitude for their dedication and impactful contributions over the years.
Peter Taylor, MA, PhD, FRCP, FRCPE
Emeritus Professor of Musculoskeletal Sciences, University of Oxford
Marco Londei, MD
Biotech Executive, Company Founder, Board Member, Physician Scientist, Drug Developer
Deepak A. Rao, MD, PhD
Associate Professor of Medicine and Associate Physician, Harvard Medical School
Co-Director, Center for Cellular Profiling, Brigham and Women’s Hospital
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage biotech pioneering curative immunotherapies for patients with unmet medical needs. The company is targeting the root cause of disease through its unique Drug Intelligence Science (DIS®) platform. DIS® enables a deep understanding of cellular and molecular pathology across various diseases through proprietary single cell technology and AI/ML analytics. This platform is being deployed in target discovery, antibody selection, and predictive biomarker identification to achieve enhanced clinical success for patients. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized globally for its innovative drug development capabilities. For additional information, please visit www.hifibio.com
HiFiBiO® is a trademark of HiFiBiO Therapeutics and its affiliates